Biofilm-encapsulated nano drug delivery system for the treatment of colon cancer. (2nd October 2020)

• Record Type: Journal Article
• Authors: Shi, Jinyan; Ma, Zhiwei; Pan, Hao; Liu, Yang; Chu, Yuqi; Wang, Jinglei; Chen, Lijiang
• Is Part Of: Journal of microencapsulation. Volume 37:Number 7(2020)
• Page Start: 481
• Page End: 491
• Publication Date: 2020-10-02
• Subjects: Composite carrier -- Escherichia coli's outer membrane vesicles -- mesoporous silica -- oral administration -- colon cancer therapy; Microencapsulation -- Periodicals; Controlled release technology -- Periodicals; 615.19
• DOI: 10.1080/02652048.2020.1797914
• Languages: English
• ISSNs: 0265-2048

Abstract

Abstract: Aim: In this study, 5-fluorouracil (5-FU) is delivered to target colon without the interference of mononuclear phagocyte system (MPS). Methods: Outer membrane vesicles (OMVs) were used as the biological shield to disguise mesoporous silica (MSN) and 5-FU. OMVs-MSN-5-FU were prepared by high pressure co-extrusion, and characterised on the basis of size, drug loading, transmission electron microscope, infra-red spectroscopy, differential scanning calorimetry, thermal gravity analysis, % in vitro release, MTT assay, cell uptake and in vivo imaging. Results: OMVs-MSN-5-FU with −18.22 ± 0.17 mV zeta potential and 90.4 ± 9.1 nm size were used for oral treatment of colon cancer. Drug loading of the drug was 50.22%±0.17 (w/w). The cumulative release of OMVs-MSN-5-FU reached 75.07%±0.94 in tumour microenvironment. The percentage of cell viability of OMVs-MSN-5-FU was 33.75%±2.73. In vivo experiments results confirmed that OMVs-MSN-5-FU could be taken up by colon cancer cells. Conclusions: The study provided a promising nano platform for the targeting treatment of colon cancer.